Sun Pharma approved a ₹3,000 crore investment to build a formulation manufacturing unit in Madhya Pradesh. The decision was recorded in the company’s exchange filing and outlines capital allocation for the upcoming facility without forward-looking statements.
As quoted in the press release from Sun Pharma and its news (NSE Exchange Filings), Sun Pharma approved an investment plan of ₹3,000 crore to build a formulations manufacturing unit in Madhya Pradesh. The official filing stated the decision and listed the capital amount, the type of facility and the location. The update also noted that the approval followed the company’s regular governance process.
The statement outlined the plan in clear terms. It listed the proposed spend for construction, equipment and essential systems required for the unit. Sun Pharmaceutical Industries Limited and share price remains an important part of public updates, as such information is relevant for listed company disclosures. The filing did not include forward-looking points and stayed within confirmed facts.
Also read: Canara Bank Raises ₹3,500 Crore through AT1 Bonds at 7.55%
Approved investment: ₹3,000 crore
Purpose: Formulations manufacturing unit
Location: Madhya Pradesh
Source: Exchange filing from Sun Pharma
Also read: KPI Green Energy Secures ₹489 Cr Floating Solar EPC Order
The filing confirmed that Sun Pharmaceutical Industries Limited approved ₹3,000 crore for a new formulation manufacturing unit. This approval was documented through a formal board decision. It recorded the use of funds for infrastructure, machinery and key systems needed for the unit.
The statement focused on the nature of the project. It explained that the investment will support work such as building structures, installing equipment and creating utility systems. Each detail in the update came from the formal filing. There were no extended comments or assumptions, and no links to future outcomes.
The filing mentioned that the new unit will focus on formulations. It stated that the investment will cover setup activities needed to build a functional manufacturing facility. This includes site development, equipment installation and related technical systems.
The project description stayed limited to confirmed details. The document did not discuss production capacity or timelines. Instead, it kept the focus on the approval, the type of unit and the location. The communication explained the administrative nature of the decision. It reflected the company’s standard format for reporting large investments made through board approval.
Particulars | Details |
Approving Authority | Sun Pharma Board |
Investment Value | ₹3,000 crore |
Project Type | Formulations Manufacturing Unit |
Location | Madhya Pradesh |
Source | Exchange Filing |
The filing recorded the capital allocation as part of routine business communication. It confirmed the investment without adding predictions or market views. The statement placed the project within the company’s usual manufacturing and operational plans.
As on 02-Dec-2025 at 15:30 PM IST, Sun Pharmaceutical Industries Limited share price stood at ₹1,804.90, reflecting a movement of -₹2.50 (-0.14%). The session recorded a previous close of ₹1,807.40, an open of ₹1,804.00, a high of ₹1,814.90, and a low of ₹1,788.60. The VWAP stood at ₹1,797.04, and the close price was ₹1,799.50.
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading